Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

doravirine-lamiVUDine-tenofovir disoproxil fumarate

doravirine-lamiVUDine-tenofovir disoproxil fumarate
  • Non-formulary
  • Therapeutic Interchange
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Delstrigo TABLET, ORAL 100 mg-300 mg-300 mg    
Comments:
 
Ordered Formulation Therapeutic Interchange

doravirine-lamiVUDine-tenofovir disoproxil fumarate (Delstrigo)

  • 100 mg-300 mg- 300 mg oral tablet

doravirine (Pifeltor) AND lamiVUDine (Epivir) AND tenofovir disoproxil fumarate (Viread)

  • ONE 100 mg doravirine tablet PLUS ONE 300 mg lamiVUDine tablet PLUS ONE 300 mg tenofovir disoproxil fumarate tablet

Non-formulary. Patient may use home supply. If patient unable to use their own medication each individual component will be dispensed.

Reviewed: 26 Feb 2019 (Delstrigo)

 
Last updated: Feb. 26, 2019






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved